Form 4: Orchestra BioMed Director Eric Fain Awarded Significant Equity Compensation

Orchestra BioMed Holdings, Inc. Director Eric S. Fain has been granted 12,422 restricted stock units and 36,797 stock options, aligning his interests with the company's long-term performance.

Summary

• Eric S. Fain, a Director of Orchestra BioMed Holdings, Inc. (OBIO), reported the acquisition of equity securities.
• On June 24, 2025, Mr. Fain was awarded 12,422 restricted stock units (RSUs) at a price of $0 per unit.
• These RSUs represent a contingent right to receive one share of Common Stock per unit.
• The RSUs will vest in one installment on the earlier of (x) the one-year anniversary of the Grant Date (June 24, 2025) or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to Mr. Fain's continuous service.
• Following this transaction, Mr. Fain indirectly beneficially owns 53,632 shares of Common Stock through the Fain Living Trust.
• Additionally, on June 24, 2025, Mr. Fain was granted 36,797 stock options with an exercise price of $3.22 per share.
• The stock options were acquired at a price of $0 and have an expiration date of June 24, 2035.
• These stock options will also vest in one installment on the earlier of (x) the one-year anniversary of the Grant Date (June 24, 2025) or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to Mr. Fain's continuous service.
• Following this transaction, Mr. Fain directly beneficially owns 36,797 stock options.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation award to a director, which is generally a positive signal as it aligns management's interests with shareholders. There are no negative financial or operational details.

Positives

• The equity awards to Director Eric S. Fain align his financial interests directly with the long-term performance and shareholder value creation of Orchestra BioMed Holdings, Inc.
• The grant of restricted stock units and stock options is a common practice for executive and director compensation, indicating a commitment to retaining key personnel.

Risks

• The vesting of both the restricted stock units and stock options is subject to Eric S. Fain's continuous service to the company through the specified vesting dates, meaning the awards could be forfeited if service ceases prematurely.

Future Outlook

The future outlook for these awards is tied to the company's performance and the continued service of Director Eric S. Fain, with vesting scheduled for the earlier of the one-year anniversary of the grant date or the 2026 Annual Meeting of Stockholders.

Industry Context

The granting of equity awards such as restricted stock units and stock options to directors is a standard practice across various industries, particularly in the biotechnology and medical device sectors where long-term value creation and retention of experienced leadership are critical. This practice aims to align the interests of directors with those of shareholders, incentivizing them to contribute to the company's sustained growth and success.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this filing, the structure of equity awards (RSUs and stock options) with performance-based or time-based vesting is a common compensation mechanism for directors in publicly traded companies, particularly those in growth-oriented sectors like biotech.
• The exercise price of $3.22 for the stock options would typically be set at or above the market price on the grant date, which is standard practice to ensure future value creation for the options.

Related Party Transactions

• The equity awards (restricted stock units and stock options) granted to Eric S. Fain, a Director of Orchestra BioMed Holdings, Inc., constitute a related party transaction as they involve compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the director's interests with those of shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.
• Management: The awards incentivize the director to remain engaged and contribute to the company's success.

Next Steps

• Vesting of the 12,422 restricted stock units on the earlier of June 24, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders.
• Vesting of the 36,797 stock options on the earlier of June 24, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders.
• Potential exercise of stock options by Eric S. Fain after vesting and before the expiration date of June 24, 2035.

Key Dates

Keywords

Orchestra BioMed Holdings Inc., OBIO, SEC Form 4, Insider Transaction, Equity Award, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Beneficial Ownership, Executive Compensation